Biodexa Pharmaceuticals Files Routine 6-K Report
Ticker: BDRX · Form: 6-K · Filed: Mar 10, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Mar 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: routine-filing, foreign-private-issuer, sec-disclosure
Related Tickers: BDRX
TL;DR
Biodexa (BDRX) filed a 6-K, just a routine update, no new info.
AI Summary
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on March 10, 2025. This report is for the month of March 2025 and indicates the company files annual reports under Form 20-F. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure for a foreign private issuer.
Why It Matters
This filing is a standard disclosure for foreign private issuers, indicating ongoing compliance with SEC reporting requirements without providing new material information.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not contain new material information that would typically impact risk.
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Registrant
- Midatech Pharma Plc (company) — Former company name
- 001-37652 (other) — Commission File Number
- 20250310 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.
What is Biodexa Pharmaceuticals PLC's former name?
Biodexa Pharmaceuticals PLC's former name was Midatech Pharma Plc, with a date of name change on June 2, 2015.
What is the company's principal executive office address?
The company's principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Does Biodexa Pharmaceuticals PLC file annual reports under Form 20-F?
Yes, the filing indicates by check mark that the registrant files annual reports under cover of Form 20-F.
Is the information in Exhibit 99.1 considered 'filed' for Section 18 of the Exchange Act?
No, the information in the attached Exhibit 99.1 is being furnished and shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 10, 2025 regarding Biodexa Pharmaceuticals Plc (BDRX).